European Innovation Council

BOYDSense is a medical device company founded in 2015 and headquartered in South San Francisco, California. The company specializes in developing non-invasive and affordable tools for measuring critical biomarkers through exhaled breath. BOYDSense focuses on breath-based metabolomics, which involves capturing, identifying, and quantifying volatile organic compound (VOC) biomarker patterns found in human breath. This innovative approach enables medical professionals to simplify the monitoring, screening, and risk stratification of chronic diseases, facilitating more effective diagnosis and ongoing management of these conditions.

NETRIS Pharma S.A.S. is a biotechnology company based in Lyon, France, focused on the identification and development of therapeutic molecules aimed at treating various forms of cancer. Established in 2008, the company specializes in targeting dependence receptors, which are trans-membrane proteins that play a crucial role in cellular signaling and tumor control. NETRIS Pharma conducts both in vitro and in vivo research, as well as preclinical practices, to manufacture drugs specifically for the treatment of breast cancer, lung cancer, glioblastoma, and neuroblastoma. Through its innovative approach, the company aims to advance cancer therapies and contribute to improved patient outcomes in the pharmaceutical industry.

Neuro Event Labs Oy, established in 2015 and headquartered in Tampere, Finland, specializes in developing artificial intelligence-based software for epilepsy patient monitoring. Their primary product collects accurate seizure data from patients at home and in hospitals, which is then analyzed and relayed to physicians for informed treatment decisions. This solution was developed in close collaboration with leading Finnish hospitals.

Cellbox Solutions is a technology company that specializes in innovative logistic solutions for the global BioMed industry. It has developed a carbon dioxide incubator designed for the storage, isolation, handling, and analysis of biological materials. This incubator offers essential logistic services and ensures the proper handling of living cells, facilitating their storage, reproduction, transportation, and analysis. By enabling the transportation of living cells via various methods, including road, rail, and air, Cellbox Solutions supports healthcare providers in their efforts to deliver the latest therapies to patients.

InProTher Aps is a biotechnology company based in Copenhagen, Denmark, focusing on the development of innovative vaccine technologies and candidates within the field of immunotherapy. Established in 2011, the company is dedicated to creating the first adaptive immune therapy that targets immunosuppressive genes associated with ancient retroviruses. InProTher is also engaged in the development of products aimed at combating HIV, papilloma viruses, and various forms of cancer. Through its research and development efforts, InProTher seeks to advance treatment options in the evolving landscape of immunotherapy.

GrayMatters Health is a health technology company focused on developing digital therapeutics for mental disorders by enabling volitional regulation of brain processes. The company aims to address mental health and neurological disorders through its innovative solutions, which empower healthcare professionals with neuroscience-based technology. By targeting brain biomarkers associated with these conditions, GrayMatters Health enhances the efficacy, safety, and accessibility of mental healthcare. This approach provides patients with streamlined treatment options, allowing them to manage their disorders more effectively and conveniently.

Brainhero is a life science company that specializes in home-based neurofeedback therapy aimed at assisting individuals with neurological impairments, particularly children diagnosed with Autism Spectrum Disorder (ASD) and Attention Deficit Hyperactivity Disorder (ADHD). The company utilizes an innovative approach that enables users to train their brain activity through an engaging and playful interface. By measuring brain waves with an electroencephalogram (EEG) and visualizing the data in a mobile application, children can learn to enhance their concentration and relaxation skills. Brainhero's services also support medical practitioners in early prediction of neurological issues and in adjusting medication dosages for patients experiencing various conditions, including intellectual disabilities, epilepsy, and anxiety.

ALA Diagnostics specializes in the development and marketing of in vitro diagnostic kits aimed at addressing prevalent pathologies and unresolved medical needs. The company focuses on creating diagnostic solutions, including kits specifically designed for the early diagnosis of multiple sclerosis. These kits are engineered for seamless integration into the clinical routines of hospitals and medical centers, allowing healthcare professionals to deliver accurate results efficiently. By improving diagnostic capabilities, ALA Diagnostics contributes to enhancing the quality of life for individuals affected by multiple sclerosis and potentially other conditions, leveraging synergies with public organizations renowned for their innovative project initiatives.

Lattice Medical is a French company founded in 2017 that specializes in the design and manufacture of cell regeneration prostheses for women who have undergone mastectomy due to breast cancer. The company addresses the needs of a significant population, as one in eight women is diagnosed with breast cancer, and a substantial percentage undergo mastectomy procedures. Lattice Medical has developed an innovative implantable device called MATTISSE, which facilitates natural breast reconstruction by regenerating autologous adipose tissues. Utilizing advanced technologies such as biomaterials, tissue engineering, and 3D printing, MATTISSE allows for personalized reconstruction in a single surgical procedure. The device is composed of fully biodegradable materials that dissolve post-reconstruction, aiming to replace traditional silicone-based implants. This approach not only enhances the surgical experience by reducing invasiveness and pain but also significantly decreases surgery time, providing health professionals with a valuable tool for restoring patients' bodies and lives.

Celeris Therapeutics is an AI-first drug discovery company that focuses on developing proximity-inducing compounds (PICs), particularly PIC degraders, to address high unmet medical needs in diseases like Parkinson's and various cancers. The company has created the Celeris One platform, which utilizes structure-based geometric deep learning to enhance the design and development of degraders by prioritizing specific E3 ligases, designing effective linkers, and selecting optimal compounds for synthesis. Additionally, Celeris Therapeutics operates an in-house automated laboratory that facilitates rapid generation of experimental data for further optimization. The company collaborates with pharmaceutical and biotech firms to discover and develop small-molecule degrader therapies across multiple therapeutic areas, while also advancing its own internal drug pipeline. Celeris Therapeutics maintains offices in Menlo Park, California, and Graz, Austria.

Celeris Therapeutics is an AI-first drug discovery company that focuses on developing proximity-inducing compounds (PICs), particularly PIC degraders, to address high unmet medical needs in diseases like Parkinson's and various cancers. The company has created the Celeris One platform, which utilizes structure-based geometric deep learning to enhance the design and development of degraders by prioritizing specific E3 ligases, designing effective linkers, and selecting optimal compounds for synthesis. Additionally, Celeris Therapeutics operates an in-house automated laboratory that facilitates rapid generation of experimental data for further optimization. The company collaborates with pharmaceutical and biotech firms to discover and develop small-molecule degrader therapies across multiple therapeutic areas, while also advancing its own internal drug pipeline. Celeris Therapeutics maintains offices in Menlo Park, California, and Graz, Austria.

AuriGen Medical Limited is an innovative company based in Dublin, Ireland, specializing in electrophysiology and structural heart solutions. Founded in 2016, AuriGen develops advanced left atrial appendage (LAA) implants aimed at addressing the stroke and arrhythmia risks associated with persistent atrial fibrillation (AF). The company targets a significant and growing patient population, particularly those with medication-resistant AF, which affects over three million individuals across the United States and Europe. AuriGen's technology offers a novel trans-septal implant that not only treats AF effectively but also reduces the reliance on anticoagulants and anti-arrhythmic medications. By providing cost-effective treatment options, AuriGen aims to improve patient outcomes while addressing the rising financial burden of managing chronic cardiac conditions in aging populations.

PhosPrint, established in 2019 and headquartered in Agia Paraskevi, Attiki, specializes in laser bioprinting systems and regenerative medicine. The company's core business involves developing and providing on-site cell printing during surgeries, aiming to facilitate tissue regeneration and advance medical research. PhosPrint's offerings include healthcare technology products that leverage laser bioprinting and biotechnology research, enabling researchers and medical professionals to access innovative tools and procedures to combat diseases and medical conditions.

Betalin Therapeutics is a privately-held company dedicated to developing innovative cell therapy solutions for insulin-dependent diabetes through its Engineered Micro-Pancreas (EMP) technology. This platform combines harvested pancreatic islets, known as Islets of Langerhans, with a proprietary biological micro-environment designed to support these cells. The EMP aims to offer an alternative to traditional insulin therapy, potentially eliminating the need for insulin injections and glucose monitoring in patients. Following promising in-vitro and preliminary in-vivo results, Betalin Therapeutics is focused on optimizing the therapy using animal models and preparing to submit an Investigational New Drug (IND) application to the FDA in anticipation of advancing to clinical trials.

Cardiac Success is a medical technology company focused on developing innovative solutions to enhance cardiac function in patients suffering from heart failure and functional mitral regurgitation. The company's flagship product, the V-sling device, is a transcatheter ventricular repair device that draws upon a proven surgical technique known as papillary muscle approximation. This device aims to provide relief to patients experiencing heart failure with reduced ejection fraction, enabling them to improve their quality of life and manage critical heart conditions more effectively. Through its advancements, Cardiac Success strives to address significant challenges in cardiac care and contribute to better health outcomes for individuals with heart-related ailments.

GrayMatters Health is a health technology company focused on developing digital therapeutics for mental disorders by enabling volitional regulation of brain processes. The company aims to address mental health and neurological disorders through its innovative solutions, which empower healthcare professionals with neuroscience-based technology. By targeting brain biomarkers associated with these conditions, GrayMatters Health enhances the efficacy, safety, and accessibility of mental healthcare. This approach provides patients with streamlined treatment options, allowing them to manage their disorders more effectively and conveniently.

BOYDSense is a medical device company founded in 2015 and headquartered in South San Francisco, California. The company specializes in developing non-invasive and affordable tools for measuring critical biomarkers through exhaled breath. BOYDSense focuses on breath-based metabolomics, which involves capturing, identifying, and quantifying volatile organic compound (VOC) biomarker patterns found in human breath. This innovative approach enables medical professionals to simplify the monitoring, screening, and risk stratification of chronic diseases, facilitating more effective diagnosis and ongoing management of these conditions.

Askel Healthcare is a medical device company focused on advancing knee cartilage repair and recovery. The company offers a science-backed solution designed to rebuild the knee joint surface, facilitating a quicker return to an active and pain-free life for patients. Askel's innovative device provides evidence-based solutions in the field of cartilage repair, aiming to prevent osteoarthritis and improve treatment outcomes in veterinary medicine. By enabling healthcare providers to treat more patients efficiently and at a lower cost, Askel Healthcare contributes to enhanced patient care with reduced complications and faster rehabilitation processes.

InProTher Aps is a biotechnology company based in Copenhagen, Denmark, focusing on the development of innovative vaccine technologies and candidates within the field of immunotherapy. Established in 2011, the company is dedicated to creating the first adaptive immune therapy that targets immunosuppressive genes associated with ancient retroviruses. InProTher is also engaged in the development of products aimed at combating HIV, papilloma viruses, and various forms of cancer. Through its research and development efforts, InProTher seeks to advance treatment options in the evolving landscape of immunotherapy.

Op2Lysis is a biotechnology company focused on developing innovative treatments for hemorrhagic stroke. The company specializes in a thrombolytic drug designed to dissolve intracerebral hematomas, which are blood clots that can lead to significant disability if not addressed. This drug utilizes vectorization technology and is intended to be administered locally through a catheter, allowing for micro-invasive surgical procedures. By effectively liquefying the hematoma, Op2Lysis aims to provide patients with a safer alternative to major surgeries, thereby improving recovery outcomes and reducing long-term disabilities associated with hemorrhagic strokes.

NETRIS Pharma S.A.S. is a biotechnology company based in Lyon, France, focused on the identification and development of therapeutic molecules aimed at treating various forms of cancer. Established in 2008, the company specializes in targeting dependence receptors, which are trans-membrane proteins that play a crucial role in cellular signaling and tumor control. NETRIS Pharma conducts both in vitro and in vivo research, as well as preclinical practices, to manufacture drugs specifically for the treatment of breast cancer, lung cancer, glioblastoma, and neuroblastoma. Through its innovative approach, the company aims to advance cancer therapies and contribute to improved patient outcomes in the pharmaceutical industry.

NETRIS Pharma S.A.S. is a biotechnology company based in Lyon, France, focused on the identification and development of therapeutic molecules aimed at treating various forms of cancer. Established in 2008, the company specializes in targeting dependence receptors, which are trans-membrane proteins that play a crucial role in cellular signaling and tumor control. NETRIS Pharma conducts both in vitro and in vivo research, as well as preclinical practices, to manufacture drugs specifically for the treatment of breast cancer, lung cancer, glioblastoma, and neuroblastoma. Through its innovative approach, the company aims to advance cancer therapies and contribute to improved patient outcomes in the pharmaceutical industry.

Op2Lysis is a biotechnology company focused on developing innovative treatments for hemorrhagic stroke. The company specializes in a thrombolytic drug designed to dissolve intracerebral hematomas, which are blood clots that can lead to significant disability if not addressed. This drug utilizes vectorization technology and is intended to be administered locally through a catheter, allowing for micro-invasive surgical procedures. By effectively liquefying the hematoma, Op2Lysis aims to provide patients with a safer alternative to major surgeries, thereby improving recovery outcomes and reducing long-term disabilities associated with hemorrhagic strokes.

Fibriant is a biotechnology startup specializing in the development and production of recombinant fibrinogen, a crucial protein involved in blood clotting, tissue repair, and immune response. The company utilizes an advanced biotechnology platform to create flexible and biodegradable fibrinogen variants. These variants are designed to regulate essential biological processes, including wound healing, tissue remodeling, and inflammation. Fibriant's products are particularly beneficial for healthcare organizations, addressing complications associated with vein grafts following bypass surgery by preventing both early and late-stage graft failure. Through its innovative approach, the company aims to enhance patient outcomes in various medical contexts.

Cardiac Success is a medical technology company focused on developing innovative solutions to enhance cardiac function in patients suffering from heart failure and functional mitral regurgitation. The company's flagship product, the V-sling device, is a transcatheter ventricular repair device that draws upon a proven surgical technique known as papillary muscle approximation. This device aims to provide relief to patients experiencing heart failure with reduced ejection fraction, enabling them to improve their quality of life and manage critical heart conditions more effectively. Through its advancements, Cardiac Success strives to address significant challenges in cardiac care and contribute to better health outcomes for individuals with heart-related ailments.

Fibriant is a biotechnology startup specializing in the development and production of recombinant fibrinogen, a crucial protein involved in blood clotting, tissue repair, and immune response. The company utilizes an advanced biotechnology platform to create flexible and biodegradable fibrinogen variants. These variants are designed to regulate essential biological processes, including wound healing, tissue remodeling, and inflammation. Fibriant's products are particularly beneficial for healthcare organizations, addressing complications associated with vein grafts following bypass surgery by preventing both early and late-stage graft failure. Through its innovative approach, the company aims to enhance patient outcomes in various medical contexts.

GrayMatters Health is a health technology company focused on developing digital therapeutics for mental disorders by enabling volitional regulation of brain processes. The company aims to address mental health and neurological disorders through its innovative solutions, which empower healthcare professionals with neuroscience-based technology. By targeting brain biomarkers associated with these conditions, GrayMatters Health enhances the efficacy, safety, and accessibility of mental healthcare. This approach provides patients with streamlined treatment options, allowing them to manage their disorders more effectively and conveniently.

Lattice Medical is a French company founded in 2017 that specializes in the design and manufacture of cell regeneration prostheses for women who have undergone mastectomy due to breast cancer. The company addresses the needs of a significant population, as one in eight women is diagnosed with breast cancer, and a substantial percentage undergo mastectomy procedures. Lattice Medical has developed an innovative implantable device called MATTISSE, which facilitates natural breast reconstruction by regenerating autologous adipose tissues. Utilizing advanced technologies such as biomaterials, tissue engineering, and 3D printing, MATTISSE allows for personalized reconstruction in a single surgical procedure. The device is composed of fully biodegradable materials that dissolve post-reconstruction, aiming to replace traditional silicone-based implants. This approach not only enhances the surgical experience by reducing invasiveness and pain but also significantly decreases surgery time, providing health professionals with a valuable tool for restoring patients' bodies and lives.

PROSION is a biotechnology company focused on developing innovative drug therapies for challenging medical conditions, particularly cancer and other hard-to-treat diseases such as diabetes, Alzheimer's, and cardiovascular diseases. Utilizing a proprietary platform, PROSION aims to target proline-rich motif binding domains, which are often considered undruggable. By leveraging unique chemical building blocks, the company seeks to unlock these difficult pharmaceutical targets, addressing significant unmet medical needs. Through its research and development efforts, PROSION strives to enhance treatment options and improve the survival and quality of life for patients facing these serious health challenges.

InProTher Aps is a biotechnology company based in Copenhagen, Denmark, focusing on the development of innovative vaccine technologies and candidates within the field of immunotherapy. Established in 2011, the company is dedicated to creating the first adaptive immune therapy that targets immunosuppressive genes associated with ancient retroviruses. InProTher is also engaged in the development of products aimed at combating HIV, papilloma viruses, and various forms of cancer. Through its research and development efforts, InProTher seeks to advance treatment options in the evolving landscape of immunotherapy.

HIL Applied Medical is developing a new class of ultra-compact, high-performance accelerators for proton therapy. HIL applies a patented approach to particle acceleration and beam delivery, combining nano-technology with ultra-high-intensity lasers and ultra-fast magnets. These technological breakthroughs enable meaningful reduction in the size, complexity and cost of proton therapy systems, without compromising clinical utility. Thus HIL aims to enable, for the first time, a single-room add-on proton therapy solution that is truly cost-effective. HIL Applied Medical is a privately-held company, backed by VCs and global strategic partners. It is headquartered in the High-Tech Park, Givat Ram, Jerusalem, Israel; and have a wholly-owned subsidiary in Reno, Nevada (United States).

Quantib is a company that specializes in developing advanced radiology software aimed at enhancing the diagnostic capabilities of physicians. Its innovative software leverages machine learning techniques to analyze medical images, specifically MRI and CT scans, facilitating the segmentation, classification, quantification, and visualization of data. By automating and streamlining workflows, Quantib's solutions enable healthcare professionals to make more efficient and accurate diagnoses. The company's commitment to improving healthcare outcomes is evident in its focus on addressing the complex challenges faced by radiologists, ultimately helping to unveil details in medical images that may not be visible to the naked eye.

Neuro Event Labs Oy, established in 2015 and headquartered in Tampere, Finland, specializes in developing artificial intelligence-based software for epilepsy patient monitoring. Their primary product collects accurate seizure data from patients at home and in hospitals, which is then analyzed and relayed to physicians for informed treatment decisions. This solution was developed in close collaboration with leading Finnish hospitals.

Betalin Therapeutics is a privately-held company dedicated to developing innovative cell therapy solutions for insulin-dependent diabetes through its Engineered Micro-Pancreas (EMP) technology. This platform combines harvested pancreatic islets, known as Islets of Langerhans, with a proprietary biological micro-environment designed to support these cells. The EMP aims to offer an alternative to traditional insulin therapy, potentially eliminating the need for insulin injections and glucose monitoring in patients. Following promising in-vitro and preliminary in-vivo results, Betalin Therapeutics is focused on optimizing the therapy using animal models and preparing to submit an Investigational New Drug (IND) application to the FDA in anticipation of advancing to clinical trials.

Neuro Event Labs Oy, established in 2015 and headquartered in Tampere, Finland, specializes in developing artificial intelligence-based software for epilepsy patient monitoring. Their primary product collects accurate seizure data from patients at home and in hospitals, which is then analyzed and relayed to physicians for informed treatment decisions. This solution was developed in close collaboration with leading Finnish hospitals.

Betalin Therapeutics is a privately-held company dedicated to developing innovative cell therapy solutions for insulin-dependent diabetes through its Engineered Micro-Pancreas (EMP) technology. This platform combines harvested pancreatic islets, known as Islets of Langerhans, with a proprietary biological micro-environment designed to support these cells. The EMP aims to offer an alternative to traditional insulin therapy, potentially eliminating the need for insulin injections and glucose monitoring in patients. Following promising in-vitro and preliminary in-vivo results, Betalin Therapeutics is focused on optimizing the therapy using animal models and preparing to submit an Investigational New Drug (IND) application to the FDA in anticipation of advancing to clinical trials.

MoveUP is a company focused on developing and commercializing digital therapeutics solutions designed to enhance healthcare delivery. Its innovative platform features a closed-loop system that ensures high compliance and improved outcomes for patients. By continuously collecting data, the platform personalizes treatment plans, significantly enhancing patient satisfaction. MoveUP's initial product targets orthopedic patients recovering from joint surgery, providing a user-friendly medical-grade mobile application that supports faster recovery. The company holds CE medical device and ISO 13485 certifications, underscoring its commitment to quality and regulatory standards in the healthcare sector.

MoveUP is a company focused on developing and commercializing digital therapeutics solutions designed to enhance healthcare delivery. Its innovative platform features a closed-loop system that ensures high compliance and improved outcomes for patients. By continuously collecting data, the platform personalizes treatment plans, significantly enhancing patient satisfaction. MoveUP's initial product targets orthopedic patients recovering from joint surgery, providing a user-friendly medical-grade mobile application that supports faster recovery. The company holds CE medical device and ISO 13485 certifications, underscoring its commitment to quality and regulatory standards in the healthcare sector.

Desentum Oy, established in 2011 and headquartered in Finland, is a biopharmaceutical company dedicated to developing innovative allergy vaccines. The company focuses on creating hypoallergenic vaccines targeting common allergens such as birch pollen, pet dander, and food proteins like fish and nuts. Desentum's unique approach involves designing vaccines that switch the immune system's response from hypersensitivity to tolerance, aiming to provide long-term relief for allergy sufferers while reducing societal burdens.